Nephros Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 97 out of 156 in the Professional & Commercial Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Nephros Inc is 7.74, ranking 48 out of 156 in the Professional & Commercial Services industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 4.76M, representing a year-over-year increase of 35.42%, while its net profit experienced a year-over-year increase of 84.15%.
Key Metrics
The current valuation score of Nephros Inc is 4.82, ranking 150 out of 156 in the Professional & Commercial Services industry. Its current P/E ratio is 27.66, which is 774.30% below the recent high of 241.82 and 190.12% above the recent low of -24.93.
The current earnings forecast score of Nephros Inc is 8.00, ranking 31 out of 156 in the Professional & Commercial Services industry. The average price target is 7.00, with a high of 8.00 and a low of 6.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Nephros Inc is 6.63, ranking 113 out of 156 in the Professional & Commercial Services industry. Currently, the stock price is trading between the resistance level at 4.71 and the support level at 3.42, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Nephros Inc is 3.00, ranking 111 out of 156 in the Professional & Commercial Services industry. The latest institutional shareholding proportion is 47.00%, representing a quarter-over-quarter increase of 3.59%. The largest institutional shareholder is The Vanguard, holding a total of 233.64K shares, representing 2.20% of shares outstanding, with 14.16% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Professional & Commercial Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nephros Inc is 2.33, ranking 132 out of 156 in the Professional & Commercial Services industry. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
